Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Current Deferred Revenue (2017 - 2025)

Historic Current Deferred Revenue for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $637293.3.

  • Innate Pharma's Current Deferred Revenue fell 7885.7% to $637293.3 in Q2 2025 from the same period last year, while for Jun 2025 it was $637293.3, marking a year-over-year decrease of 7885.7%. This contributed to the annual value of $658254.7 for FY2024, which is 8956.87% down from last year.
  • Latest data reveals that Innate Pharma reported Current Deferred Revenue of $637293.3 as of Q2 2025, which was down 7885.7% from $658254.7 recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Current Deferred Revenue ranged from a high of $14.3 million in Q4 2021 and a low of $637293.3 during Q2 2025
  • Its 5-year average for Current Deferred Revenue is $6.6 million, with a median of $6.3 million in 2023.
  • The largest annual percentage gain for Innate Pharma's Current Deferred Revenue in the last 5 years was 614.59% (2021), contrasted with its biggest fall of 9996.97% (2021).
  • Quarter analysis of 5 years shows Innate Pharma's Current Deferred Revenue stood at $14.3 million in 2021, then plummeted by 53.2% to $6.7 million in 2022, then fell by 5.71% to $6.3 million in 2023, then tumbled by 89.57% to $658254.7 in 2024, then fell by 3.18% to $637293.3 in 2025.
  • Its last three reported values are $637293.3 in Q2 2025, $658254.7 for Q4 2024, and $3.0 million during Q2 2024.